Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey.
Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Cancer. 2018 Oct 1;124(19):3806-3818. doi: 10.1002/cncr.31408. Epub 2018 Apr 25.
Although the majority of patients with chronic myeloid leukemia do well with treatment with tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many factors that might play a part, including the different BCR-ABL1 transcript types at baseline. The current study was performed to determine the possible impact of different transcripts on the treatment responses and outcomes of patients with chronic myeloid leukemia who are receiving TKI therapy. The authors performed a systematic literature search by using the terms "b2a2/b3a2," "e13a2/e14a2," or "transcript type." e14a2 was the more common transcript type. The majority of the studies demonstrated no significant difference regarding age, sex, leukocyte counts, and hemoglobin levels between patients with the e13a2 and e14a2 transcripts. However, in approximately one-half of the studies, the e14a2 transcript was associated with higher platelet counts. Almost no studies demonstrated a significant association between disease risk scores and transcript types. In the majority of studies, having the e14a2 transcript was associated with earlier, deeper, and higher molecular response rates. Although better event-free survival was observed in patients with the e14a2 transcript in some of the studies, the majority demonstrated that transcript type did not have an impact on progression-free and overall survival. Treatment-free remission currently is a topic of much interest, and to the authors' knowledge there are limited data with conflicting results regarding the possible effects of transcript types on the outcomes of patients after discontinuation of TKIs. Because having the e14a2 transcript appears to be related to a favorable outcome, choosing second-generation TKIs for frontline therapy might be a convenient approach in patients with chronic myeloid leukemia with the e13a2 transcript. The authors believe this finding warrants further investigation.
虽然大多数慢性髓性白血病患者通过酪氨酸激酶抑制剂(TKI)治疗效果良好,但仍有部分患者预后较差。有许多因素可能起作用,包括基线时不同的 BCR-ABL1 转录本类型。本研究旨在确定不同转录本对接受 TKI 治疗的慢性髓性白血病患者的治疗反应和结局可能产生的影响。作者使用“b2a2/b3a2”、“e13a2/e14a2”或“转录本类型”等术语进行了系统的文献检索。e14a2 是更为常见的转录本类型。大多数研究显示,e13a2 和 e14a2 转录本患者在年龄、性别、白细胞计数和血红蛋白水平方面无显著差异。然而,约有一半的研究显示,e14a2 转录本与较高的血小板计数相关。几乎没有研究表明疾病风险评分与转录本类型之间存在显著关联。在大多数研究中,e14a2 转录本与更早、更深和更高的分子反应率相关。尽管一些研究显示,e14a2 转录本与更好的无事件生存相关,但大多数研究表明转录本类型对无进展和总生存无影响。无治疗缓解目前是一个备受关注的话题,据作者所知,关于转录本类型对 TKI 停药后患者结局的可能影响,仅有少数数据且结果相互矛盾。由于 e14a2 转录本似乎与良好的结局相关,因此对于携带 e13a2 转录本的慢性髓性白血病患者,选择第二代 TKI 作为一线治疗可能是一种便捷的方法。作者认为这一发现值得进一步研究。